Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Hims & Hers stories

Nov 6, 2026

Eli Lilly strikes deal to sell obesity drugs directly on Hims & Hers platform

Eli Lilly announced a partnership allowing Hims & Hers Health to sell its obesity drugs Zepbound and Foundayo directly on the telehealth platform, sending Hims & Hers shares up more than 7%. The deal marks a significant course change for Hims, which had previously sold compounded GLP-1 knockoffs.

Nov 6, 2026·3 sources
00
Aug 10, 2026

Hims & Hers posts wider loss as shift to branded weight-loss drugs drives up costs

Hims & Hers Health reported a wider-than-expected second-quarter loss as the telehealth company's shift to branded weight-loss drugs drove up costs, sending shares down 6% in extended trading. The company plans to enter the peptides market before year-end.

Aug 10, 2026·3 sources
00
Jul 29, 2026

FTC sues Hims & Hers over sharing users' health information with advertisers

The Federal Trade Commission, Utah, and Los Angeles County sued telehealth company Hims & Hers Health for allegedly misleading consumers about its products and sharing private health information with advertisers. Shares fell 10% following the announcement.

Jul 29, 2026·2 sources
00

Top claims

  • ▪Novo Nordisk treatments available on Hims & Hers start at $149 per month for the Wegovy pill and $199 per month for the Wegovy injector pen
  • ▪Prior to the November 6, 2026 partnership, Hims & Hers patients had to leave the platform and navigate to LillyDirect to obtain Eli Lilly obesity drugs
  • ▪Leerink Partners analyst Michael Cherny described the November 6, 2026 agreement with Eli Lilly as a clear positive that completes Hims & Hers' effort to secure access to major GLP-1 drugmakers

Topics

FoundaoObesity treatmentZepboundEli LillyRetatrutideNovo NordiskDrug Policy, Pricing & ApprovalDrug pricingGLP-1 / Weight-Loss MedicationsCompounding pharmaciesGLP-1 medicationsPharmaceutical IndustryHealthcare costsWeight managementCorporate earningsDigital health platformsCompounded peptidesPharmaFederal Trade CommissionerAI data privacy & biometric surveillanceRegulatory complianceConsumer protectionAI privacy & surveillanceGovernment and Regulatory PolicyAI regulation & lawsuitsPublic healthcareHealthcare fraud & litigation

Related entities

WegovyOzempicTelehealth